The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials - 27/02/13
, John B. Hagan, MD a, Miguel A. Park, MD a, Jenna C. Podjasek, MD a, Shefali A. Samant, MD a, Gerald W. Volcheck, MD a, Patricia J. Erwin, MLS b, Colin P. West, MD, PhD c, d
Corresponding author: Matthew A. Rank, MD, Division of Allergic Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905.Abstract |
Background |
Current asthma guidelines suggest that patients and their providers consider decreasing or stopping controller medications when asthma is stable.
Objective |
We sought to estimate the risk of asthma exacerbation in patients who stop low-dose inhaled corticosteroids (ICSs) compared with those who continue ICSs in randomized controlled trials.
Methods |
We identified relevant trials from a systematic review of English-language and non–English-language articles using MEDLINE, EMBASE, and CENTRAL (inception to January 21, 2012). Articles were screened at the abstract and full-text level by 2 independent reviewers. We included randomized controlled trials with a stable asthma run-in period of 4 weeks or more, an intervention to stop or continue ICSs, and a follow-up period of at least 3 months. We pooled results using a random-effects meta-analysis.
Results |
The search strategy identified 1798 potential articles, of which 172 were reviewed at the full-text level and 7 met the criteria for inclusion. The relative risk for an asthma exacerbation in patients who stopped ICSs compared with those who continued use was 2.35 (95% CI, 1.88-2.92; P < .001; I2 = 0%), as determined by using data pooled from trials with a mean follow-up of 27 weeks. The pooled absolute risk difference for an asthma exacerbation was 0.23 (95% CI, 0.16-0.30; P < .001; I2 = 44%). Patients who discontinued ICSs also had a decreased FEV1 of 130 mL (95% CI, 40-210 mL; P = .003; I2 = 53%), a decreased mean morning peak expiratory flow of 18 L/min (95% CI, 6-29 L/min; P = .004; I2 = 82%), and an increased mean standardized asthma symptom score of 0.43 SDs (95% CI, 0.28-0.58 SDs; P < .001; I2 = 0%).
Conclusion |
Patients with well-controlled asthma who stop regular use of low-dose ICSs have an increased risk of an asthma exacerbation compared with those who continue ICSs.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, antiasthma agents, glucocorticoids, clinical trial, step down, withdraw, discontinue, decrease, wean, cessation
Abbreviations used : ICS, LABA, NAEPP, PEF, PRISMA, RR
Plan
| Supported by the Mayo Foundation. |
|
| Disclosure of potential conflict of interest: M. A. Rank is employed by the Mayo Clinic. J. B. Hagan is the Dyac Chairman of Adjudication panel for KALBITOR; has received research support from the National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, MedImmune, and the Mayo Foundation; is inventor of technology to assess asthma therapy adherence; and previously owned stock in Johnson & Johnson and Teva. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 131 - N° 3
P. 724 - mars 2013 Retour au numéro
Article précédent
- Peripheral airway impairment measured by oscillometry predicts loss of asthma control in children
- Yixin Shi, Anna S. Aledia, Stanley P. Galant, Steven C. George
- Maternal smoking affects lung function and airway inflammation in young children with multiple-trigger wheeze
- Satu Kalliola, Anna S. Pelkonen, L. Pekka Malmberg, Seppo Sarna, Mauri Hämäläinen, Ilkka Mononen, Mika J. Mäkelä
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?